| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
|
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS |
|
Bone Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates |
|
Blood Advances |
Aplastic Anemia |
| Outpatient transfusions for myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study |
|
BMJ Supportive & Palliative Care |
Myelodysplastic Syndromes (MDS) |
